ST迪瑞 reported revenue of ¥0.41B for the period ended 2026-06-30, +16.5% year on year. Net income was ¥0.01B, a 1.9% net margin on a 45.3% gross margin. The largest revenue line is 试剂 at 61% of the total. Free cash flow for the period was ¥-0.10B.
| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥0.41B | +16.5% |
| Gross profit | ¥0.19B | — |
| Operating income | ¥0.01B | — |
| Net income | ¥0.01B | — |
| Gross margin | 45.3% | Net margin 1.9% |
| Revenue Q/Q | +29.8% | — |
| Segment | Revenue | Share |
|---|---|---|
| 试剂 | ¥0.25B | 61.2% |
| 仪器 | ¥0.16B | 38.4% |
| 其他(补充) | ¥0.00B | 0.4% |
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥0.22B | 54.7% |
| R&D | ¥0.05B | 11.4% |
| SG&A | ¥0.12B | 28.2% |
| Tax & other | ¥-0.00B | -0.1% |
| Item | Amount |
|---|---|
| Total assets | ¥2.57B |
| Total liabilities | ¥1.02B |
| Shareholders' equity | ¥1.55B |
| Equity / assets | 60.3% |
| Operating cash flow | ¥-0.09B |
| Capital expenditure | ¥0.01B |
| Free cash flow | ¥-0.10B |
| Cash conversion (OCF / net income) | -1497% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
天和防务 ・ 飞凯材料 ・ 天利科技 ・ 劲拓股份 ・ 花园生物 ・ 宝色股份 ・ 汉宇集团 ・ 博济医药 ・ 科隆股份 ・ 九强生物 ・ 凯发电气 ・ 道氏技术
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies